"New Study on ‘Breakthrough’ Atopic Dermatitis Drug Indicates ‘Eczema Is An Autoimmune Disease’"
Researchers behind a new study on the atopic dermatitis drug “dupilumab” (which is currently in trials) say that they have proven that this form of eczema is an autoimmune disease. The potential atopic dermatitis medication blocks the activity of two key immune proteins, interleukin-4 (IL-4) and interleukin-13 (IL-13), and according to the researchers, can reverse the immune response within an allergic individual that causes the atopic dermatitis skin problems. The promising new atopic dermatitis drug study was led by Emma Guttman-Yassky, MD, Associate Professor of Dermatology at the Icahn School of Medicine at Mount Sinai. Learn more.
Mount Sinai Study Reveals Genetic Clues Explaining Why Obesity Affects People Differently
Sep 15, 2025 View All Press Releases
Mount Sinai Launches Cardiac Catheterization Artificial Intelligence Research Lab
Sep 15, 2025 View All Press Releases
Lung Cancer Rewires Immune Cells in the Bone Marrow to Weaken Body’s Defenses
Sep 10, 2025 View All Press Releases
Single Hair Strand Could Provide Biomarker for ALS, Mount Sinai Study Finds
Sep 04, 2025 View All Press Releases
New AI Tool Addresses Accuracy and Fairness in Data to Improve Health Algorithm
Sep 04, 2025 View All Press Releases
Mount Sinai Study Discovers Potential Link Between Stress and Type 2 Diabetes
Sep 03, 2025 View All Press Releases